Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614134 | 1.00 | PPM1B (0.49) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL28403234 | 1.00 | PPM1B (0.49) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL16405665 | 1.00 | PPM1B (0.49) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL34472936 | 0.92 | PPM1B (0.46) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL34468392 | 0.87 | PPM1B (0.46) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL32677632 | 0.81 | PPM1B (0.44) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL32677631 | 0.81 | PPM1B (0.44) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL15712143 | 0.80 | PPM1B (0.53) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL23780231 | 0.78 | — | — | |
| SCHEMBL5778032 | 0.78 | PPM1B (0.43) | PPM1BPTPN1PPP1CCMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110582485-B | Pyrazole derivatives as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-3589618-B1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| EP-3692026-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| US-11273146-B2 | Benzofuran derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-03-15 | — | — | US | disclosed |
| US-10966961-B2 | Pyrazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-04-06 | — | — | US | disclosed |
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3440069-B1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-20200289464-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200291009-A1 | 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| EP-3440075-B1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-08-06 | — | — | US | disclosed |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-05-23 | — | — | US | disclosed |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
| US-20180282301-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2018158212-A1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | PPM1B 1176/4885PTPN1 2541/4885PPP1CC 3358/4885 |
| US-20200289464-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRPF3 | PPM1B 2100/4885PTPN1 4220/4885PPP1CC 3963/4885 |
| US-10966961-B2 | Pyrazole derivatives as bromodomain inhibitors | BRD3, BRD4, BRPF3 | PPM1B 465/4885PTPN1 2285/4885PPP1CC 2105/4885 |
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | BRD4, BRD3, BRDT | PPM1B 497/4885PTPN1 1850/4885PPP1CC 3032/4885 |
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | BRD4, BRD3, BRD2 | PPM1B 490/4885PTPN1 2957/4885PPP1CC 3254/4885 |
| US-11273146-B2 | Benzofuran derivatives and their use as bromodomain inhibitors | BRD4, BRD3, BRPF3 | PPM1B 2100/4885PTPN1 4220/4885PPP1CC 3963/4885 |
| US-20200291009-A1 | 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD3 | PPM1B 1367/4885PTPN1 3405/4885PPP1CC 3865/4885 |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | PPM1B 497/4885PTPN1 1850/4885PPP1CC 3032/4885 |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | PPM1B 490/4885PTPN1 2957/4885PPP1CC 3254/4885 |
| US-20180282301-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | PPM1B 1176/4885PTPN1 2541/4885PPP1CC 3358/4885 |
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | BRD4, BRD3, BRPF3 | PPM1B 1214/4885PTPN1 3470/4885PPP1CC 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.